September 19, 2016 08:22 AM EDT

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

Arsalan Arif

Founder

San Diego-based Vical $VICL says that its lead vaccine ASP0113 flopped in a Phase II study designed to thwart herpes in kidney transplant patients. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lead vaccine from Vical and Astellas flops in a Phase II herpes study

Arsalan Arif

Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Novo Nordisk claims late-stage MASH victory, continuing GLP-1's expansion

Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47M

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Exclusive: Women’s health unicorn Maven Clinic cuts 10% of its workforce weeks after raising $125M

Q&A: Jade CEO talks about reverse merger and IgAN drugs

Lead vac­cine from Vi­cal and Astel­las flops in a Phase II her­pes study

Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Lead vaccine from Vical and Astellas flops in a Phase II herpes study